#prospect-evaluation

#prospect-evaluation

Awards may be encouraging and occasionally useful for visibility, but they are weak indicators of validation and poor predictors of long-term success. In the longevity and healthspan industry, where timelines are long and claims are easy to overstate, venture capital ultimately follows alignment and evidence, not applause received at glitzy industry events.

However, alongside these tangible indicators sits another layer of value, one that does not always surface cleanly in financial statements and may even remain invisible if it is not properly understood or articulated: Put simply, intangible assets are the non-physical elements a company has built that enable it to generate revenue, scale efficiently, or defend its market position. In technology companies, this typically includes proprietary software, intellectual property, datasets, customer relationships, brand equity, and internal systems or processes.

I don't take founders here for exercise. I take them here because the controlled environment of a boardroom practically demands rehearsed answers. The trail does not. I don't prepare a script for these walks. In fact, that's the point. The pitch is already done; I know the metrics. Now I want to know the human.

The ETF holds 50 positions, but the top two dominate in a way that makes the rest almost incidental. Johnson & Johnson carries a 25.4% weight, and Eli Lilly and Company sits at 21.4%. Together they account for roughly 46.8% of the entire fund.

Start-up founders often underestimate the power of public relations, but doing so comes at a cost: at best, missed opportunities; at worst, a crisis that spirals out of control without a lifeline. PR is not a glossy "top coat" applied to a finished product or milestone. Entrepreneurs would do better to see it as a foundational tool that creates organizational wins, not just announces them.

Heat looks like validation, and validation looks like safety. It is hard to ignore a sector when customers start leaning forward at the same time investors do. Still, the more cycles I have lived through in competitive technology businesses, the more I see heat as an optical illusion. It sharpens whatever is easiest to notice and blurs the underlying mechanics that determine who or what holds control.

The Schwab U.S. Small-Cap ETF (NYSEARCA:SCHA) has delivered a 5.5% return YTD, tracking the broader small-cap market's trajectory. The fund's defining advantage is cost efficiency, at a scant 0.04% annual expense ratio ranks among the lowest in the small-cap category, allowing investors to compound returns without significant fee drag eating into performance over time. Recent coverage has been mixed. MSN positioned SCHA as an "attractive option" given its low costs and past performance.